177Lu-PSMA-617 improves rPFS in taxane-naïve metastatic castration-resistant prostate cancer
However, lack of OS benefit limits the clinical impact of the findings from the PSMAfore trial
Antibody–drug conjugates improve outcomes for patients with inoperable or metastatic breast cancer
Promising results reported for datopotamab deruxtecan and trastuzumab deruxtecan in HER2-non-amplified breast cancer
Amivantamab combination therapies emerge as new options for EGFR-mutated advanced NSCLC
Clinically meaningful improvements over standard care were observed in both first and second line, as reported in the MARIPOSA and MARIPOSA-2 phase III trials
Improved results from cellular therapies thanks to AI and bioinformatic platforms
Positive signals from early-phase studies suggest that newer molecular technologies may help to disclose the promises of T-cell therapies in different settings
Digital health technologies help revolutionise patient-centred cancer care
Recent studies show how digital health apps enhance the patient experience, and improve multiple quality of life domains and in some cases, adherence to treatment, but their integration into the healthcare system is still a challenge
Transforming cancer care through collaborative research
Successful partnerships between industry and academia has had a positive impact on cancer drug discovery and development in prostate cancer
Study provides new evidence linking air pollution with increased breast cancer risk
Epidemiological data from France underline the urgent need for public policy and advocacy to improve air quality around the world
Invasive breast cancer: can surgery be eliminated after neoadjuvant systemic chemotherapy?
Phase II data report a pathologic complete response in patients who received radiotherapy after neoadjuvant therapy without surgery, when selected by image-guided vacuum-assisted core biopsy
Sustained efficacy of CDK inhibitors reported for HR+/HER2– early breast cancer
Long-term data from monarchE supports dose reduction while NATALEE data reinforces consistency across subgroups
Aspirin in colorectal cancer – has it still a place in secondary prevention?
Negative results from the ASCOT trial should not discourage researchers from investigating the drug’s potential in some molecularly distinct subgroups